SBI Biotech Co., Ltd. is a bio-venture firm envisaged and founded by SBI Holdings President & CEO, Mr. Yoshitaka Kitao and Molecular Biologist, Dr. Ken-ichi Arai.
SBI Biotech is
Venture that links latest achievement in life science to state-of-the-art treatment and innovative drug discovery.
Venture that can promote drug development from seed discovery to clinical studies.
Venture that identifies promising drug seeds and develops drug pipelines from the world.
Global venture wherein researchers from Japan, U.S., Israel, China, Korea and the other countries to cooperate across borders.
Company Fact Sheet
As of December 31, 2017
|Company Name||SBI Biotech Co., Ltd.|
|Capital||100,000 thousand Yen|
|Board of Directors
(As of April 10, 2018)
|Date of Foundation||March 30,2001|
|Head Office||Izumi Garden Tower 15F|
1-6-1 Roppongi, Minato-ku Tokyo 106-6015Map
|Principal affiliates||Quark Pharmaceuticals, Inc.|
6501Dumbarton Circle, Fremont,California, USA
Origin of Company Name
We named our company "SBI Biotech" to indicate our wishes, as the first bio-venture firm in the SBI Group, to contribute to society through commercializing various promising and innovative drug seeds.